MANCHESTER, England--(BUSINESS WIRE)--Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials took over its first site in Kiev at the world renowned Centre for Radiation Medicine in January this year when it finalised its acquisition of ClinPharm.
Chief Executive of Synexus, Michael Fort says growth for 2010 and beyond is already looking very encouraging: “Interest from sponsors to use all of our sites in the CEE has been incredibly strong so far this year, but I am particularly impressed with the levels of interest in Ukraine. We have a number of very highly qualified investigators at the site in Kiev who specialise in diabetes, immunology and neurology and who have excellent relationships with colleagues in primary and secondary care. This is proving key to working with sponsors to set up trials here.”
The Kiev site is presently in discussions about its involvement in a number of international type 2 diabetes trials, and is predicted to recruit well in excess of its targets far more quickly than comparable sites in Western Europe and the UK.
Jane Restorick, Chief Operating Officer for Synexus expects pharma and CROs to place more studies in the Ukraine and take advantage of the largely treatment naïve population there: “In Kiev alone we have a population in excess of 2.5 million. Our site is part of an extremely modern and highly regarded hospital where specialist consultants have very positive relationships with our investigators. On top of this, we are working with patients who are keen to join clinical trials so that they can benefit from higher standards of healthcare than they might otherwise afford. The drop out rates here are considerably lower than in Western Europe and the doctor-patient relationship is generally stronger and with higher levels of respect and trust.”